Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

350.30
+5.551.61%
Post-market: 348.00-2.3000-0.66%19:30 EDT
Volume:380.66K
Turnover:131.29M
Market Cap:9.76B
PE:-27.23
High:351.72
Open:343.00
Low:333.46
Close:344.75
52wk High:392.70
52wk Low:37.19
Shares:27.85M
Float Shares:24.08M
Volume Ratio:1.22
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:7.28
PE(LYR):-25.99

Loading ...

How Investors May Respond To Praxis (PRAX) FDA Priority Review For Rare Pediatric Epilepsy Drug

Simply Wall St.
·
Apr 04

Praxis grants inducement RSUs covering 3,558 shares to 18 new employees

Reuters
·
Apr 03

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), PepGen Inc. (PEPG) and Omeros (OMER)

TIPRANKS
·
Apr 01

Jefferies Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Mar 31

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Mar 31

Praxis Precision Medicines Secures US FDA Priority Review for Epilepsy Drug Application

MT Newswires Live
·
Mar 31

Praxis Precision announces FDA acceptance for priority review of relutrigine NDA

TIPRANKS
·
Mar 31

Praxis NDA for relutrigine wins FDA priority review, PDUFA date set for Sept. 27, 2026

Reuters
·
Mar 31

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients With Scn2a and Scn8a Dees

THOMSON REUTERS
·
Mar 31

Praxis Precision Medicines Inc - Relutrigine Emerald Trial for Broad Dees Expected to Complete by End of 2026

THOMSON REUTERS
·
Mar 31

Praxis Precision Medicines Inc - FDA Assigns Pdufa Target Action Date of Sept 27, 2026 for Relutrigine

THOMSON REUTERS
·
Mar 31

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Biohaven Ltd. (BHVN) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
Mar 11

Praxis Precision Medicines Grants 2,931 RSUs Under 2024 Inducement Plan

Reuters
·
Mar 05

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 05

Praxis Precision Med Initiated at Outperform by Wolfe Research

Dow Jones
·
Feb 24

Praxis Precision initiated with an Outperform at Wolfe Research

TIPRANKS
·
Feb 24

Praxis Precision Medicines Maps Aggressive Path to Market

TIPRANKS
·
Feb 23